knowledge -WSS

knowledge

author：explore 2025-09-28 01:37:12 - browse：16

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

leisure time

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: How researchers deal with rejection

Pig kidney works a record two months in donated body

IRA could hurt research into orphan drugs for rare diseases

hotspot

knowledge

Wikipedia

Psychedelics group wrestles with new pharma identity

Diverse clinical trials: Why aren’t we there yet?

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Summit: Meghan O’Rourke on making chronic illness visible

In age of alternative facts, a scholarly course on calling out crap

J&J lung cancer data amount to new salvo against AstraZeneca

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: Live from the 2023 STAT Summit

23andMe had bad news about my health. I wish a person had delivered it

STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

Popular nasal decongestant doesn't actually relieve congestion

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Regeneron agrees to White House price limits on anti

How medical schools plan to diversify without affirmative action

Generate Biomedicines machine learning biotech raises $273M

STAT Summit: How researchers deal with rejection

hotspot

knowledge

leisure time

hotspot